NDUFB4
ENSG00000065518
Target class
Enzyme
Chromosome
3
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- B15
- Target name
- NDUFB4
- Gene name
- NADH:ubiquinone oxidoreductase subunit B4
- Gene symbol
- NDUFB4
- Protein name
- NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 (Complex I-B15) (CI-B15) (NADH-ubiquinone oxidoreductase B15 subunit)
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 159.34
- Tissue specificity (Gini)
- 0.161
- Tissue specificity (tau)
- 0.459
- KEGG gene identifiers
- hsa:4710
- Protein interaction confidence
- 0.93334
- Protein interaction partners
- 94
- R-HSA-611105
- R-HSA-6799198
- End position
- 120602507
- Start position
- 120596303
- Chromosome
- 3
- Strand
- Forward
- Mitochondrion inner membrane
- Single-pass membrane protein
- Matrix side .
- Mitochondria
- Nuclear membrane
- Nucleoplasm
- Principal piece
Publication evidence
- PubMed 12611891
- Tissue specificity (tau)
- 0.459337
- Expression inequality (Gini)
- 0.161035
Expression in transcripts per million
- Adrenal Gland
- 159.34
- Heart - Left Ventricle
- 143.15
- Muscle - Skeletal
- 142.73
- Brain - Cerebellar Hemisphere
- 138.64
- Cells - EBV-transformed lymphocytes
- 135.35
Expression in transcripts per million
- Adrenal Gland159.34
- Heart - Left Ventricle143.15
- Muscle - Skeletal142.73
- Brain - Cerebellar Hemisphere138.64
- Cells - EBV-transformed lymphocytes135.35
- Pituitary117.54
- Heart - Atrial Appendage114.62
- Brain - Cerebellum112.23
- Cervix - Ectocervix105.01
- Vagina103.05
- Artery - Tibial102.72
- Uterus100.27
- Colon - Sigmoid100.15
- Esophagus - Gastroesophageal Junction99.92
- Cervix - Endocervix99.88
- Esophagus - Muscularis99.18
- Kidney - Medulla97.73
- Artery - Aorta96.33
- Artery - Coronary95.82
- Ovary95.79
- Adipose - Subcutaneous92.53
- Thyroid92.19
- Breast - Mammary Tissue90.1
- Testis89.02
- Prostate86.76
And 29 more, listed on the interactive page.
- GO:0005739
- GO:0005743
- GO:0045271
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor